AZN

MKT CAP:$293B

AstraZeneca PLC

Market Cap

$293B

Healthcare·Drug Manufacturers - General·🇬🇧 United Kingdom·NYSE

Healthcare·Drug Mfg.·🇬🇧·NYSE

Stock Price

$189.01+$6.33 (+3.47%)

Apr 24, 2026

Company Details

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpa...

CEO

Pascal Claude Roland Soriot

IPO Date

May 12, 1993

Website

www.astrazeneca.com

Key Metrics TTM

Revenue

$44.4B

— YoY

Net Income

$7.0B

EPS (Diluted)

$9.38

Free Cash Flow

$9.6B

Revenue / Share

$56.90

Gross Margin

80.3%

Operating Margin

22.2%

Net Margin

15.8%

FCF Margin

21.6%

P/S

6.6x

P/E

41.8x

Earnings Reports

Q4 2025

May 5, 2026

PENDING

FY 2025

Feb 24, 2026

$58.7BEPS $13.08

Q3 2025

Nov 6, 2025

$15.2BEPS $3.24

Q1 2025

Mar 30, 2025

$13.6BEPS $3.74

Q2 2021

Jun 29, 2021

$8.2BEPS $0.84

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q4 20	$7.4B	$5.9B	$1.5B
Q2 21	$8.2B	$6.0B	$1.1B
Q1 25	$13.6B	$11.3B	$3.7B
Q3 25	$15.2B	$12.4B	$3.6B

Valuation

Quarter	P/S	P/E
Q4 20	—	—
Q2 21	—	—
Q1 25	—	—
Q3 25	10.3x	65.2x

Operating Cash Flow

Quarter	Operating CF	Free CF
Q4 20	$1.8B	$1.3B
Q2 21	$892M	$604M
Q1 25	$3.7B	$3.3B
Q3 25	$5.1B	$4.4B

Capital Expenditures

Quarter	CapEx
Q4 20	$548M
Q2 21	$288M
Q1 25	$429M
Q3 25	$686M

CapEx

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q4 20	$0	0.0%
Q2 21	$0	0.0%
Q1 25	$0	0.0%
Q3 25	$0	0.0%

OpEx Breakdown

Quarter	R&D	G&A	S&M
Q4 20	$2.0B	—	$5.1B
Q2 21	$1.8B	$3.1B	$103M
Q1 25	$3.2B	$4.5B	$135M
Q3 25	$3.7B	$5.1B	$148M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$5.8B	$61M	$5.8B
Q2 22	$4.8B	$70M	$4.9B
Q3 22	$4.5B	$440M	$4.9B
Q4 22	$6.2B	$77M	$6.2B
Q1 23	$6.2B	$230M	$6.5B
Q2 23	$5.7B	$148M	$5.8B
Q3 23	$4.9B	$244M	$5.1B
Q4 23	$5.8B	$20M	$5.9B
Q1 24	$7.8B	$180M	$8.0B
Q2 24	$6.9B	$160M	$7.1B
Q3 24	$4.8B	$133M	$4.9B
Q4 24	$5.5B	$166M	$5.7B
Q1 25	$5.2B	$165M	$5.4B
Q2 25	$7.1B	$50M	$7.1B
Q3 25	$8.1B	$39M	$8.2B
Q4 25	$5.7B	$30M	$5.7B

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q4 20	657M	—	—
Q2 21	659M	+0.4%	—
Q1 25	781M	+18.4%	—
Q3 25	781M	0.0%	—

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q4 20	$37.0K	200K
Q2 21	$41.1K	200K
Q1 25	$7M	2K
Q3 25	$8M	2K

Revenue / Employee